A month ago, SAP co-founder Dietmar Hopp managed a stroke of genius: The foundation of Bill and Belinda Gates got in on one of his biotech investments. After the SAP foundation, it is one of the most successful investment of Hopp.
Investor Dietmar Hopp looks after the home of Bill Gates in his biotech participation Curevac another candidate. “Curevac is probably the most successful investment be” Dietmar Hopp told Deutsche Presse-Agentur. “But I see two or three others, should have great success.”
In early March made headlines because the foundation of Microsoft founder Bill Gates was joined at the biotech company Curevac. Hopp is concerned about his investment company Dievini with about 90 percent of Curevac. The biotech company based in Tübingen developing drugs based on the messenger RNA (mRNA) and in the field, according to experts pioneer.
Originally 16 companies given money to the SAP co-founder. “Of the nine who are still on board, is probably one of the investment return. All others should have success,” Hopp announced. These included beside the developer of nicotine patches and patches for the treatment of Parkinson’s disease, Lohmann Therapy Systems, including Alzheimer’s specialist AC Immune and Molecular Health. The company processed molecular data into clinically useful information to develop personalized cancer therapies.
Hopp had begun after his retirement from business operations of SAP at the turn of the millennium to invest in biotechnology. “I expected that Lifesciences the next wave will be according to the information processing,” explains the 74-year-old pivot software to biotechnology. “I was then invest 500 million euros, now it’s more than a billion euros.” As the biggest flop he sees his involvement in two companies that have focused on the health card. “That cost me a lot of money and we had to dismantle many jobs.”
Two years ago, the faith had solidified, “from the investments that have survived are less great success more or “. Eventually, the investments are to bear, so Hopps plan. “We want to set as a cycle going to return flows from new investments to make,” he says. “It will still take a while.” In the case of Curevac Hopp makes hopes for an IPO could wash into the coffers of the company’s new money: “It could be that we dare with Curevac might end, despite the local restraint, the IPO in Germany,” he said . in a recent interview ( Annika Graf, dpa ) / ( pmz)
No comments:
Post a Comment